Article preview from Start-Up - March 01, 2011
According to "US Markets for Peripheral Vascular Stents," a report recently published by the Medtech Insight division of Elsevier Business Intelligence, the peripheral vascular stent market yielded more than $1 billion in revenues in the US in 2009, and will continue to grow at an overall rate of 7.2% in coming years, with some product segments growing even faster. Stents for carotid arteries are expected to yield a 36.5% annual compound growth rate through 2014 and endovascular products for the repair of aortic aneurysms (AAA) will grow by 8.4%, according to the Medtech Insight report. AAA endografts accounted for 43.7% of peripheral vascular stent sales last year.
Article preview from Start-Up - March 01, 2011
After three decades of dramatic innovation in coronary artery disease, peripheral vascular disease has moved up in the evolutionary chain. With the mature coronary artery space now offering low single-digit growth rates, medical device companies of all sizes are looking to the product opportunities in peripheral arterial disease, a market estimated to grow by 10 to 12% per year from its current level of $3 to $3.5 billion. Two major acquisitions in the space have underscored the opportunities. In January 2010, Medtronic Inc. paid $350 million plus earn-outs to acquire Invatec SPA, which, beginning in peripheral vascular disease, captured the European market and is now bringing its strategy to the US. Five months later, Covidien Ltd. acquired ev3 Inc., a major presence in non-coronary percutaneous interventions with some 100 such products. The medical device industry has officially recognized that peripheral vascular disease is not an extension of interventional cardiology, but is in need of innovation directed at peripherally specific products. This recognition has extended beyond arterial disease to new markets opening up in venous disease.
According to " US Markets for Peripheral Vascular Stents," a report recently published by the Medtech Insight division of Elsevier Business Intelligence, the peripheral vascular stent market yielded more than $1 billion in revenues in the US in 2009, and will continue to grow at an overall rate of 7.2% in coming years, with some product segments growing even faster. Stents for carotid arteries are expected to yield a 36.5% annual compound growth rate through 2014 (although from a low base of $111 million in 2010) and endovascular products for the repair of aortic aneurysms (AAA) will grow by 8.4%, according to the Medtech Insight report. AAA endografts accounted for 43.7% of peripheral vascular stent sales last year. This segment, dominated by Medtronic, which holds an almost 33% market share, Cook Group Inc., with a 32% market share, and WL Gore & Associates Inc., with an almost 30% share, produced revenues of approximately $570 million in 2010, making it the largest product in the peripheral vascular stent market today, followed by stents for lower extremity arteries, which generated $468 million in revenues in 2010.
Continued...
To read this article in its entirety, Purchase now as a PDF and receive it immediately via email. Or get it FREE when you subscribe to Start-Up.
About Start-Up
No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
.jpg)
Comments